^
    Back
    Association details:
    Biomarker:IGHG1 overexpression
    Cancer:Triple Negative Breast Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Phase II Clinical Trial of Pembrolizumab and Chemotherapy Reveals Distinct Transcriptomic Profiles by Radiologic Response in Metastatic Triple-Negative Breast Cancer

    Published date:
    10/26/2023
    Excerpt:
    IGHG1high tumors were associated with improved overall survival (p=0.045) and were concurrently enriched with B cells and follicular helper T cells, indicating IGHG1 as a promising marker for lymphocytic infiltration and robust response to chemo-immunotherapy...Patients with ≤2 prior therapies for metastatic disease were treated with CNP regardless of tumor PD-L1 status.
    Secondary therapy:
    carboplatin + albumin-bound paclitaxel
    DOI:
    10.1158/1078-0432.CCR-23-1349